Differential senolytic inhibition of normal versus Aβ-associated cholinesterases: implications in aging and Alzheimer's disease – PubMed Black Hawk Supplements

Abstract

Cellular senescence is a hallmark of aging and the age-related condition, Alzheimer’s disease (AD). How senescence contributes to cholinergic and neuropathologic changes in AD remains uncertain. Furthermore, little is known about the relationship between senescence and cholinesterases (ChEs). Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are important in neurotransmission, cell cycle regulation, and AD amyloid-β (Aβ) pathology. Senolytic agents have shown therapeutic promise in AD models. Therefore, we evaluated in vitro and in silico activity of senolytics, dasatinib (1), nintedanib (2), fisetin (3), quercetin (4), GW2580 (5), and nootropic, meclofenoxate hydrochloride (6), toward AChE and BChE. As ChEs associated with AD pathology have altered biochemical properties, we also evaluated agents 1-6 in AD brain tissues. Enzyme kinetics showed agents 1, 3, 4, and 6 inhibited both ChEs, while 2 and 5 inhibited only AChE. Histochemistry showed inhibition of Aβ plaque-associated ChEs (1 and 2: both ChEs; 5: BChE; 6: AChE), but not normal neural-associated ChEs. Modeling studies showed 1-6 interacted with the same five binding locations of both ChEs, some of which may be allosteric sites. These agents may exert their beneficial effects, in part, by inhibiting ChEs associated with AD pathology and provide new avenues for development of next-generation inhibitors targeting pathology-associated ChEs.

Keywords: acetylcholinesterase; butyrylcholinesterase; cellular senescence; cholinesterase inhibitors; β-amyloid.

Similar articles

• Discovery of novel hybrid tryptamine-rivastigmine molecules as potent AChE and BChE inhibitors exhibiting multifunctional properties for the management of Alzheimer’s disease.

  Shankar G, Kumar P, Rai S, Ghosh A, Varma T, Wani MA, Kumar S, Mandloi U, Singh GK, Garg P, Kulkarni O, Srikrishna S, Kumar S, Modi G. Shankar G, et al. Eur J Med Chem. 2025 Feb 5;283:117066. doi: 10.1016/j.ejmech.2024.117066. Epub 2024 Nov 27. Eur J Med Chem. 2025. PMID: 39667052

• Discovery of novel substituted (Z)-N’-hydroxy-3-(3-phenylureido)benzimidamide derivatives as multifunctional molecules targeting pathological hallmarks of Alzheimer’s disease.

  Shankar G, Praveen Kumar C, Yadav M, Ghosh A, Panda SR, Banerjee A, Tiwari A, Rai S, Kumar S, Garg P, Naidu VGM, Kulkarni O, Modi G. Shankar G, et al. Eur J Med Chem. 2024 Dec 15;280:116959. doi: 10.1016/j.ejmech.2024.116959. Epub 2024 Oct 15. Eur J Med Chem. 2024. PMID: 39461036

• Sulfonamide-Bearing Pyrazolone Derivatives as Multitarget Therapeutic Agents: Design, Synthesis, Characterization, Biological Evaluation, In Silico ADME/T Profiling and Molecular Docking Study.

  Lolak N, Akocak S, Topal M, Koçyiğit ÜM, Işık M, Türkeş C, Topal F, Durgun M, Beydemir Ş. Lolak N, et al. Pharmacol Res Perspect. 2025 Apr;13(2):e70088. doi: 10.1002/prp2.70088. Pharmacol Res Perspect. 2025. PMID: 40129107 Free PMC article.

• Pharmacological Targeting of Senescence with Senolytics as a New Therapeutic Strategy for Neurodegeneration.

  Richardson M, Richardson DR. Richardson M, et al. Mol Pharmacol. 2024 Jan 10;105(2):64-74. doi: 10.1124/molpharm.123.000803. Mol Pharmacol. 2024. PMID: 38164616 Review.

• Translating the Biology of Aging into New Therapeutics for Alzheimer’s Disease: Senolytics.

  Riessland M, Orr ME. Riessland M, et al. J Prev Alzheimers Dis. 2023;10(4):633-646. doi: 10.14283/jpad.2023.104. J Prev Alzheimers Dis. 2023. PMID: 37874084 Free PMC article. Review.

MeSH terms

Substances